RSV immunoprophylaxis: does the benefit justify the cost?
- PMID: 24127478
- DOI: 10.1542/peds.2013-2449
RSV immunoprophylaxis: does the benefit justify the cost?
Keywords: RSV prophylaxis; asthma; palivizumab; viral respiratory infection.
Comment in
-
Clarifying costs and benefits of respiratory syncytial virus immunoprophylaxis.Pediatrics. 2014 Apr;133(4):e1101. doi: 10.1542/peds.2014-0077A. Pediatrics. 2014. PMID: 24692037 No abstract available.
-
Authors' response re: Clarifying costs and benefits of respiratory syncytial virus immunoprophylaxis.Pediatrics. 2014 Apr;133(4):e1101-3. doi: 10.1542/peds.2014-0077B. Pediatrics. 2014. PMID: 24692038 No abstract available.
Comment on
-
Effect of palivizumab prophylaxis on subsequent recurrent wheezing in preterm infants.Pediatrics. 2013 Nov;132(5):811-8. doi: 10.1542/peds.2013-0982. Epub 2013 Oct 14. Pediatrics. 2013. PMID: 24127479 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical